| Grant number: | 14/23047-5 |
| Support Opportunities: | Regular Research Grants |
| Start date: | July 01, 2015 |
| End date: | June 30, 2017 |
| Field of knowledge: | Physical Sciences and Mathematics - Chemistry - Inorganic Chemistry |
| Principal Investigator: | Denise de Oliveira Silva |
| Grantee: | Denise de Oliveira Silva |
| Host Institution: | Instituto de Química (IQ). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
| City of the host institution: | São Paulo |
Abstract
Ruthenium compounds containing bioactive ligands such as non-steroidal anti-inflammatory drugs (NSAIDs) are the main focus of research in our laboratory with the purpose of finding novel metallodrugs. Compounds containing multiple metal-metal bonded Ru2(II,III) cores coordinated to NSAIDs have been found in pre-clinical studies to show anticancer properties against models of the highly malignant cerebral tumor glioblastoma multiforme (GBM). The objective of the present project is to expand our researches on this topic according to three main directions: a) synthesis and characterization of new Ru2(II,III)-NSAID complexes (with focus on structural modifications) and novel Ru(II) organometallic compounds with NSAIDs in their structures; b) studies on the interactions of the complexes with target biomolecules, e.g., amino acids and their mimetics, N-heterocyclic bases, blood proteins (human serum albumin and transferrin), DNA and oligonucleotides; c) preparation and investigation of the properties of new biocompatible nanoparticle hybrid systems formed by the interactions of the Ru2(II,III)-ibuprofen complex, the lead metallodrug, and its derivatives, with chitosans and lipids. These studies will make possible to extend the Ru-NSAID series of metallodrugs in order to try to find correlations between molecular structure and chemical and biological properties, to elucidate possible biomolecule targets and modes of action, and to exploit the viability of developing biocompatible hybrid systems for transport and drug delivery. The research may open new perspectives for bioinorganic, pharmacology and biomedical sciences by means of the development of novel drug candidates and new formulations with potential impact on the field of health targeting glioma brain cancer therapy. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |